Vondrácek Jan, Svihálková-Sindlerová Lenka, Pencíková Katerina, Krcmár Pavel, Andrysík Zdenek, Chramostová Katerina, Marvanová Sona, Valovicová Zuzana, Kozubík Alois, Gábelová Alena, Machala Miroslav
Laboratory of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, Královopolská 135, 612 65 Brno, Czech Republic.
Mutat Res. 2006 Apr 11;596(1-2):43-56. doi: 10.1016/j.mrfmmm.2005.11.005. Epub 2006 Jan 9.
Immature liver progenitor cells have been suggested to be an important target of hepatotoxins and hepatocarcinogens. The goal of the present study was to assess the impact of 7H-dibenzo[c,g]carbazole (DBC) and its tissue-specific carcinogenic N-methyl (N-MeDBC) and 5,9-dimethyl (DiMeDBC) derivatives on rat liver epithelial WB-F344 cells, in vitro model of liver progenitor cells. We investigated the cellular events associated with both tumor initiation and promotion, such as activation of aryl hydrocarbon receptor (AhR), changes in expression of enzymes involved in metabolic activation of DBC and its derivatives, effects on cell cycle, cell proliferation/apoptosis and inhibition of gap junctional intercellular communication (GJIC). N-MeDBC, a tissue-specific sarcomagen, was only a weak inhibitor of GJIC or inducer of AhR-mediated activity, and it did not affect either cell proliferation or apoptosis. DBC was efficient GJIC inhibitor, while DiMeDBC manifested the strongest AhR inducing activity. Accordingly, DiMeDBC was also the most potent inducer of cytochrome P450 1A1 (CYP1A1) and CYP1A2 expression among the three compounds tested. Both DBC and DiMeDBC induced expression of CYP1B1 and aldo-keto reductase 1C9 (AKR1C9). N-MeDBC failed to significantly upregulate CYP1A1/2 and it only moderately increased CYP1B1 or AKR1C9. Only the potent liver carcinogens, DBC and DiMeDBC, caused a significant increase of p53 phosphorylation at Ser15, an increased accumulation of cells in S-phase and apoptosis at micromolar concentrations. In addition, DiMeDBC was found to stimulate cell proliferation of contact-inhibited WB-F344 cells at 1 microM concentration, which is a mode of action that might further contribute to its hepatocarcinogenicity. The present data seem to suggest that the AhR activation, induction of enzymes involved in metabolic activation, inhibition of GJIC or stimulation of cell proliferation might all contribute to the hepatocarcinogenic effects of DBC and DiMeDBC.
未成熟的肝祖细胞被认为是肝毒素和肝癌致癌物的重要靶点。本研究的目的是评估7H-二苯并[c,g]咔唑(DBC)及其组织特异性致癌的N-甲基(N-MeDBC)和5,9-二甲基(DiMeDBC)衍生物对大鼠肝上皮WB-F344细胞(肝祖细胞的体外模型)的影响。我们研究了与肿瘤起始和促进相关的细胞事件,如芳烃受体(AhR)的激活、参与DBC及其衍生物代谢激活的酶表达的变化、对细胞周期、细胞增殖/凋亡的影响以及对间隙连接细胞间通讯(GJIC)的抑制。N-MeDBC是一种组织特异性肉瘤致癌物,只是GJIC的弱抑制剂或AhR介导活性的诱导剂,它对细胞增殖或凋亡均无影响。DBC是有效的GJIC抑制剂,而DiMeDBC表现出最强的AhR诱导活性。因此,在测试的三种化合物中,DiMeDBC也是细胞色素P450 1A1(CYP1A1)和CYP1A2表达的最有效诱导剂。DBC和DiMeDBC均诱导CYP1B1和醛酮还原酶1C9(AKR1C9)的表达。N-MeDBC未能显著上调CYP1A1/2,仅适度增加CYP1B1或AKR1C9。只有强效的肝致癌物DBC和DiMeDBC在微摩尔浓度下导致Ser15处p53磷酸化显著增加、S期细胞积累增加和凋亡。此外,发现DiMeDBC在1 microM浓度下刺激接触抑制的WB-F344细胞的增殖,这是一种可能进一步促进其肝癌发生的作用模式。目前的数据似乎表明,AhR激活、参与代谢激活的酶的诱导、GJIC的抑制或细胞增殖的刺激都可能导致DBC和DiMeDBC的肝癌致癌作用。